Published in J Med Chem on December 05, 2002
The drug-target residence time model: a 10-year retrospective. Nat Rev Drug Discov (2015) 1.13
Unbinding of retinoic acid from the retinoic acid receptor by random expulsion molecular dynamics. Biophys J (2006) 1.05
Insights into the dynamics of HIV-1 protease: a kinetic network model constructed from atomistic simulations. J Am Chem Soc (2011) 1.02
Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin. J Mol Recognit (2009) 0.99
Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin. Proteins (2009) 0.92
Strength of hydrogen bond network takes crucial roles in the dissociation process of inhibitors from the HIV-1 protease binding pocket. PLoS One (2011) 0.82
Induced maturation of human immunodeficiency virus. J Virol (2014) 0.81
Characterizing changes in the rate of protein-protein dissociation upon interface mutation using hotspot energy and organization. PLoS Comput Biol (2013) 0.80
Kinetic and thermodynamic rationale for suberoylanilide hydroxamic acid being a preferential human histone deacetylase 8 inhibitor as compared to the structurally similar ligand, trichostatin a. Biochemistry (2013) 0.78
Kinetics of the viral cycle influence pharmacodynamics of antiretroviral therapy. Biol Direct (2011) 0.77
Surface plasmon resonance as a high throughput method to evaluate specific and non-specific binding of nanotherapeutics. J Control Release (2015) 0.75
Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase. Biochemistry (2017) 0.75
Structure-Affinity Relationships and Structure-Kinetics Relationships of Pyrido[2,1-f]purine-2,4-dione Derivatives as Human Adenosine A3 Receptor Antagonists. J Med Chem (2017) 0.75
Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem (2004) 1.74
Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation (2008) 1.72
Microwave-accelerated homogeneous catalysis in organic chemistry. Acc Chem Res (2002) 1.58
In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother (2009) 1.50
Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension (2010) 1.50
Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target. Angew Chem Int Ed Engl (2010) 1.19
Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens (2009) 1.18
Structural and functional analysis of hepatitis C virus strain JFH1 polymerase. J Virol (2009) 1.17
Non-peptide AT2-receptor agonists. Curr Opin Pharmacol (2010) 1.15
Plasmepsins as potential targets for new antimalarial therapy. Med Res Rev (2006) 1.11
Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett (2008) 1.06
Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor. J Med Chem (2014) 1.05
Functionalized 3-amino-imidazo[1,2-a]pyridines: a novel class of drug-like Mycobacterium tuberculosis glutamine synthetase inhibitors. Bioorg Med Chem Lett (2009) 0.99
A new highly asymmetric chelation-controlled heck arylation. J Am Chem Soc (2003) 0.99
Formamide as a combined ammonia synthon and carbon monoxide source in fast palladium-catalyzed aminocarbonylations of aryl halides. J Comb Chem (2003) 0.99
Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone (2007) 0.97
Structural basis of ligand recognition in 5-HT3 receptors. EMBO Rep (2012) 0.96
Structural basis for the inhibition of Mycobacterium tuberculosis glutamine synthetase by novel ATP-competitive inhibitors. J Mol Biol (2009) 0.96
Short pseudopeptides containing turn scaffolds with high AT2 receptor affinity. Bioorg Med Chem (2006) 0.95
AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression. Neurobiol Dis (2012) 0.93
Mycobacterium tuberculosis ribose-5-phosphate isomerase has a known fold, but a novel active site. J Mol Biol (2004) 0.93
Synthesis, biological evaluation, and modeling studies of inhibitors aimed at the malarial proteases plasmepsins I and II. Bioorg Med Chem (2005) 0.92
Design, synthesis, and X-ray crystallographic studies of α-aryl substituted fosmidomycin analogues as inhibitors of Mycobacterium tuberculosis 1-deoxy-D-xylulose 5-phosphate reductoisomerase. J Med Chem (2011) 0.92
A selective AT2 receptor ligand with a gamma-turn-like mimetic replacing the amino acid residues 4-5 of angiotensin II. J Med Chem (2004) 0.92
Effects on protease inhibition by modifying of helicase residues in hepatitis C virus nonstructural protein 3. FEBS J (2007) 0.92
Synthesis of a new class of druglike angiotensin II C-terminal mimics with affinity for the AT2 receptor. J Med Chem (2007) 0.91
Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors. Eur J Biochem (2003) 0.91
Kinetic and thermodynamic characterization of HIV-1 protease inhibitors. J Mol Recognit (2004) 0.91
DXR inhibition by potent mono- and disubstituted fosmidomycin analogues. J Med Chem (2013) 0.91
Biosensor-based kinetic characterization of the interaction between HIV-1 reverse transcriptase and non-nucleoside inhibitors. J Med Chem (2006) 0.90
Hydrogen bonding descriptors in the prediction of human in vivo intestinal permeability. J Mol Graph Model (2003) 0.90
Dimethylformamide as a carbon monoxide source in fast palladium-catalyzed aminocarbonylations of aryl bromides. J Org Chem (2002) 0.90
Characterization of Ca2+ and phosphocholine interactions with C-reactive protein using a surface plasmon resonance biosensor. Anal Biochem (2009) 0.89
Virtual screening data fusion using both structure- and ligand-based methods. J Chem Inf Model (2011) 0.89
Identification of a novel scaffold for allosteric inhibition of wild type and drug resistant HIV-1 reverse transcriptase by fragment library screening. J Med Chem (2011) 0.89
High-speed optimization of inhibitors of the malarial proteases plasmepsin I and II. J Comb Chem (2003) 0.89
Two-carbon-elongated HIV-1 protease inhibitors with a tertiary-alcohol-containing transition-state mimic. J Med Chem (2008) 0.88
Is it possible to increase hit rates in structure-based virtual screening by pharmacophore filtering? An investigation of the advantages and pitfalls of post-filtering. J Mol Graph Model (2007) 0.88
Synthesis of potent BACE-1 inhibitors incorporating a hydroxyethylene isostere as central core. Eur J Med Chem (2009) 0.86
Interaction kinetic characterization of HIV-1 reverse transcriptase non-nucleoside inhibitor resistance. J Med Chem (2006) 0.86
Identification of MMP-12 inhibitors by using biosensor-based screening of a fragment library. J Med Chem (2008) 0.86
Design and synthesis of plasmepsin I and plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes. J Med Chem (2003) 0.86
Intramolecular Enantioselective Palladium-Catalyzed Heck Arylation of Cyclic Enamides. J Org Chem (1997) 0.85
Design and synthesis of potent and selective BACE-1 inhibitors. J Med Chem (2010) 0.85
Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV. Bioorg Med Chem (2005) 0.85
Design, synthesis and SAR of potent statine-based BACE-1 inhibitors: exploration of P1 phenoxy and benzyloxy residues. Bioorg Med Chem (2008) 0.85
Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3. Antivir Ther (2007) 0.85
Design and synthesis of potent inhibitors of plasmepsin I and II: X-ray crystal structure of inhibitor in complex with plasmepsin II. J Med Chem (2005) 0.84
Comparative functional properties of two structurally similar selective nonpeptide drug-like ligands for the angiotensin II type-2 (AT(2)) receptor. Effects on neurite outgrowth in NG108-15 cells. Eur J Pharmacol (2012) 0.84
Identification of Plasmodium falciparum spermidine synthase active site binders through structure-based virtual screening. J Med Chem (2008) 0.84
Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-Length NS3 (protease-helicase/NTPase): a comparative study of different C-terminals. Bioorg Med Chem (2003) 0.84
Selective angiotensin II AT2 receptor agonists: arylbenzylimidazole structure-activity relationships. J Med Chem (2006) 0.84
Selective angiotensin II AT2 receptor agonists: Benzamide structure-activity relationships. Bioorg Med Chem (2008) 0.84
Disulfide cyclized tripeptide analogues of angiotensin IV as potent and selective inhibitors of insulin-regulated aminopeptidase (IRAP). J Med Chem (2010) 0.84
Ligand bias of scoring functions in structure-based virtual screening. J Chem Inf Model (2006) 0.84
On the active site protonation state in aspartic proteases: implications for drug design. Curr Pharm Des (2013) 0.84
Deconstruction of non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1 for exploration of the optimization landscape of fragments. J Med Chem (2011) 0.83
Angiotensin II type 2 receptor promotes adipocyte differentiation and restores adipocyte size in high-fat/high-fructose diet-induced insulin resistance in rats. Am J Physiol Endocrinol Metab (2012) 0.83
A new regioselective Heck vinylation with enamides. Synthesis and investigation of fluorous-tagged bidentate ligands for fast separation. J Org Chem (2003) 0.83
Selective terminal heck arylation of vinyl ethers with aryl chlorides: a combined experimental-computational approach including synthesis of betaxolol. J Org Chem (2006) 0.83
Elucidation of HIV-1 protease resistance by characterization of interaction kinetics between inhibitors and enzyme variants. Antiviral Res (2003) 0.83
Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors. Bioorg Med Chem Lett (2008) 0.83
Effect of the protonation state of the titratable residues on the inhibitor affinity to BACE-1. Biochemistry (2010) 0.83
First reported nonpeptide AT1 receptor agonist (L-162,313) acts as an AT2 receptor agonist in vivo. J Med Chem (2004) 0.82
Interaction kinetic and structural dynamic analysis of ligand binding to acetylcholine-binding protein. Biochemistry (2010) 0.82
Selective angiotensin II AT(2) receptor agonists devoid of the imidazole ring system. Bioorg Med Chem (2007) 0.82
Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity. J Med Chem (2004) 0.82
Resolution of the interaction mechanisms and characteristics of non-nucleoside inhibitors of hepatitis C virus polymerase. Antiviral Res (2013) 0.82
Quantification of interactions between drug leads and serum proteins by use of "binding efficiency". Anal Biochem (2010) 0.82
A new structural theme in C2-symmetric HIV-1 protease inhibitors: ortho-substituted P1/P1' side chains. Bioorg Med Chem (2006) 0.81
2'-Deoxy-2'-spirocyclopropylcytidine revisited: a new and selective inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem (2010) 0.81
HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells. J Med Chem (2010) 0.81